Beneficial Antipsychotic Effects of Omega-3 Fatty Acids Add-On Therapy for the Pharmacological Management of Patients With Schizophrenia

Ali Manteghiy; Mohammad Taghi Shakeri; Laleh Koohestani; Elham Salari

IJ Psychiatry and Behavioral Sciences

IJPBS is the Official Journal of Mazandaran University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Publication Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Beneficial Antipsychotic Effects of Omega-3 Fatty Acids Add-On Therapy for the Pharmacological Management of Patients With Schizophrenia

Author(s):

Ali Manteghiy^1,*,

Mohammad Taghi Shakeri²,

Laleh Koohestani²,

Elham Salari²

1Ibn-E-Sina Psychiatric Hospital, Bue Ali square, Ameli Ave., Mashhad University of Medical Science and Health Services, Mashhad, Iran

2Mashhad University of Medical Sciences and Health Services, Mashhad, Iran

IJ Psychiatry and Behavioral Sciences:Vol. 2, issue 2; 35-40

Published online:Jul 31, 2008

Article type:Research Article

Received:Jun 03, 2008

Accepted:Jul 10, 2008

How to Cite:Manteghiy A, Shakeri MT, Koohestani L, Salari E. Beneficial Antipsychotic Effects of Omega-3 Fatty Acids Add-On Therapy for the Pharmacological Management of Patients With Schizophrenia. Iran J Psychiatry Behav Sci. 2008;2(2):. doi:

Abstract

Objective: It has been shown that serum and red blood cells’ level of Omega-3 fatty acids are low in people with schizophrenia. Many studies have, therefore, attempted to explore the beneficial effects of these substances in the management of Schizophrenia. However, the outcomes of the previous studies have not been clear cut.The present study is an attempt to retest this hypothesis by eliminating some of the limitations of the previous studies.

Methods: In a prospective double blind placebo-controlled clinical trial, 85 inpatients with schizophrenia randomly assigned to either risperidone plus Omega-3 or risperidone plus placebo. After a washout period, 44 patients received 2-8 mg/day of risperidone plus placebo and 43 patients received risperidone plus 3 gr/day of Omega-3 for 6 weeks. The treatment effect was calculated by Friedman, Mann Whitney and t test. There were no significant differences between groups in age, sex, education, duration of illness and the number of previous hospitalizations.

Results: There were no statistically significant differences in the scores of Positive and Negative Syndrome Scale between two groups at weeks 0, 3 and 6 and for the whole duration of the study.

Conclusion: In our study, Omega-3 fatty acids had no superiority to placebo in reducing the positive and negative symptoms of schizophrenia. However, due to a short duration of our study, we recommend that more long term clinical trials are needed in order to develop a better understanding of the therapeutic effects of the Omega-3 fatty acids in the pharmacological management of schizophrenia.

Keywords

Fulltext

Full text is available in the PDF.

References

1.
References are available in the PDF.

Omega-3 Fatty acids as Monotherapy in Treating Depression in Pregnant Women: a Meta- Analysis of Randomized Controlled Trials

Liu Wei-Hong,

Zhang Cheng-Gui,

Gao Peng-Fei,

Liu Heng,

Yang Jian-Fang

Wei-Hong L, Cheng-Gui Z, Peng-Fei G, Heng L, Jian-Fang Y. Omega-3 Fatty acids as Monotherapy in Treating Depression in Pregnant Women: a Meta- Analysis of Randomized Controlled Trials. Iran J Pharm Res. 2017;16(4):e125039. doi: https://doi.org/10.22037/ijpr.2017.2118

30

Jul

2007

Add-on Topiramate for the Pharmacological Management of Schizophrenia: A Double Blind Randomized Clinical Trial

Seyed Ghafur Mousavi,

Sharareh Golchin,

Hamid Afshar,

Hamid Reza Rooh Afza

Mousavi SG, Golchin S, Afshar H, Rooh Afza HR. Add-on Topiramate for the Pharmacological Management of Schizophrenia: A Double Blind Randomized Clinical Trial. Iran J Psychiatry Behav Sci. 2007;1(2):. doi:

26

Jan

2026

Effects of Clozapine Add-On to Risperidone vs. Risperidone Monotherapy on Agitation in Paranoid Schizophrenia: A Quasi-experimental Pilot Study

Najmiatul Fitria,

Hidayatul Arief,

Yelly Oktavia Sari,

Syofyan Syofyan

Fitria N, Arief H, Oktavia Sari Y, Syofyan S. Effects of Clozapine Add-On to Risperidone vs. Risperidone Monotherapy on Agitation in Paranoid Schizophrenia: A Quasi-experimental Pilot Study. Iran J Psychiatry Behav Sci. 2026;20(1):e164189. doi: https://doi.org/10.5812/ijpbs-164189

23

Sep

2015

Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial

Mehran Mortazavi,

Davood Farzin,

Mehran Zarhghami,

Seyed Hamzeh Hosseini,

Parisa Mansoori,

Gholamreza Nateghi

Mortazavi M, Farzin D, Zarhghami M, Hosseini SH, Mansoori P, et al. Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial. Iran J Psychiatry Behav Sci. 2015;9(3):e853. doi: https://doi.org/10.17795/ijpbs-853

31

Oct

2014

The Effects of Bupropion on Negative Symptoms in Schizophrenia

Mojtaba Yassini,

Neda Shariat,

Mohammad Nadi,

Fariba Amini,

Mohammad Vafaee

Yassini M, Shariat N, Nadi M, Amini F, Vafaee M. The Effects of Bupropion on Negative Symptoms in Schizophrenia. Iran J Pharm Res. 2014;13(4):e125587. doi: https://doi.org/10.22037/ijpr.2014.1568

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 1 week ago
Scopus by Title: 9
Last Update: 1 week ago
Scopus by Title (Ref): 10
Last Update: 1 week ago
CrossRef: 0
Last Update: 2 days ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Ali Manteghiy:[PubMed][Scholar]
Mohammad Taghi Shakeri:[PubMed][Scholar]
Laleh Koohestani:[PubMed][Scholar]
Elham Salari:[PubMed][Scholar]

IJPBS is the Official Journal of Mazandaran University of Medical Sciences

Outlines

Beneficial Antipsychotic Effects of Omega-3 Fatty Acids Add-On Therapy for the Pharmacological Management of Patients With Schizophrenia

Abstract

Fulltext

References

Similar Articles

Omega-3 Fatty acids as Monotherapy in Treating Depression in Pregnant Women: a Meta- Analysis of Randomized Controlled Trials

Add-on Topiramate for the Pharmacological Management of Schizophrenia: A Double Blind Randomized Clinical Trial

Effects of Clozapine Add-On to Risperidone vs. Risperidone Monotherapy on Agitation in Paranoid Schizophrenia: A Quasi-experimental Pilot Study

Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial

The Effects of Bupropion on Negative Symptoms in Schizophrenia

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 2 days ago